MERZ-AESTHETICS
31.3.2022 09:02:11 CEST | Business Wire | Press release
Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 20th Aesthetic & Anti-Aging Medicine World Congress (AMWC), with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diverse society. AMWC 2022, held from Thursday, 31 March to Saturday, 02 April 2022, will take place in a hybrid format, enabling participants to attend the conference in person in Monaco and/or virtually. Merz Aesthetics is an elite sponsor of the global industry congress.
“As part of our continued commitment to the aesthetic medicine industry, we are looking forward to reunite with partners and experts, share insights and foster scientific exchange in the aesthetics field at this year’s AMWC congress,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics. “We are focused to advance science in aesthetics, fuel confidence and empower unique attitudes.”
Merz Aesthetics continues to embrace the diversified and unique needs of aesthetic patients and practitioners, recognizing the personal journey for each patient and partnering with experts to meet those needs – by fueling confidence and empowering unique attitudes.
Merz Aesthetics is organizing an expert program led by esteemed medical aesthetic experts and presenting new data throughout the course of the meeting.
Expert Keynote Sessions
Merz Aesthetics is organizing expert-led keynote sessions to be held on Thursday, 31 March – Friday, 01 April (via registration only).
- “Skin Glow and Skin Quality – optimizing your skin boosting treatment” – Dr. Sonja Sattler, Thursday, 31 March, 10:00-12:00h CEST.
- “Collagen Expert Class – insights into collagen stimulation, skin quality and patient safety” – Dr. Jani van Loghem, Thursday, 31 March, 13:00-15:00h CEST.
- “Optimizing the Patient Journey in the Digital Age” – Adam Haroun, Thursday, 31 March, 15:30-17:00h CEST.
- “Aesthetic Toxin Expert Talk – purity and precision for long-term patient satisfaction” – Dr. Carla Pecora, Friday 01 April, 10:00-12:00h CEST.
- “Skin Lifting – the expert approach to customized treatments” – Dr. Tatjana Pavicic, Friday 01 April, 13:00-15:00h CEST.
- “All About Lips – expert techniques to address the unique needs of patients” – Dr. Kate Goldie, Friday 01 April, 15:30 – 17:30h CEST
Oral Presentations
Dr. Carla Pecora: ‘Clinical experience with intradermal microdroplet injection of diluted Incobotulinum toxin A for facial flushing and pore size improvement’ (Neuromodulators); Saturday, 02 April, 9:00h CEST, Nijinski
Dr. Carla Pecora: ‘A combination approach using IncobotulinumtoxinA and CPM-HA injections for the periorbital complex improvement.’ (Periorbital Zone and “Foxy Eyes” Trend – Lifting & Rejuvenating); Saturday, 02 April, 11:15h CEST, Salle des Princes & AMWC Stream 1
E-Poster Presentations
Virtual posters will be available for viewing for the duration of the congress and displayed on the virtual E-poster platform with detailed abstracts.
Botulinum Toxin
- Study Design of LONG RUN: A LONGitudinal evaluation and Real-world evidence of Uniquely purified incobotulinumtoxinA in treatment naïve participants. Andy Curry, Merz Aesthetics - USA, Terrence Keaney, MD – USA, Niamh Corduff, MD – Australia, Simon Ravichandran, MD – UK, Ada Trindade, MD – Brasil.
- Chemobioresurfacing: Does intradermal injection of botulinumtoxinA plus hyaluronic acid improve skin quality? Diane Duncan, MD – USA.
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines: Final Study Results. Martina Kerscher, MD PhD – Germany, Sabrina Fabi, Md – USA, Tanja Fischer, MD PhD – Germany, Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, PhD – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
Belotero® and Radiesse®
- The local tissue lifting capacity of dermal filler is greater with increasing hyaluronic acid concentration using an ex vivo human skin model. Kay Marquardt, Christian Hartmann, Christina Wollenburg, Tristan Gesing, Thomas Hengl – all Merz Aesthetics, Germany.
- Distance between calcium hydroxylapatite microspheres is essential for fibroblast invasion and resulting neocollagenesis. Bartosch Nowag, Nils Warfving, Thomas Hengl – all Merz Aesthetics, Germany.
- Comparative Histomorphological Evaluation of the Injectable Cohesive Polydensified Matrix Hyaluronic Acid and Calcium Hydroxylapatite Combination. Yana Yutskovskaya, MD – Russia, Evgenia Kogan, MD PhD – Russia, Alla Y Koroleva, MD – Russia.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves—however they define it. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with a commercial presence in 36 countries worldwide. Merz Aesthetics is part of Merz Group, a family-owned business founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com .
Copyright © 2022 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom